Investigating the cooperative functions of PPT1 and CLN5 in Neuronal Ceroid Lipofuscinosis - PROJECT SUMMARY Neuronal ceroid lipofuscinosis (NCLs), are a group of Mendelian, lysosomal storage disorders (LSDs) of which there are 13 subtypes (CLN1-14). NCLs are the most common neurodegenerative disease among children, with few treatment options available, leading to early mortality. Despite their shared pathological hallmarks of aberrant lipofuscin accrual and cortical atrophy, NCLs are studied independently of each other, limiting therapeutic development by tailoring them to one subtype. Our lab has focused on the most severe subtype, CLN1, in which the depalmitoylating enzyme Protein Palmitoyl Thioesterase 1 (PPT1) has loss-of-function mutations, resulting in accumulation of palmitoylated substrates, a prominent subset of which are NCL and other lysosomal storage disorder (LSD) proteins. Our most recent work shows the accrual of these palmitoylated proteins is a result of lack of their degradation, as we have found 74% of PPT1 substrates to be found in the lipofuscin proteome, implicating palmitoylation status to be a regulatory mechanism for NCL proteins. Previous work has shown another NCL protein, CLN5, to potentially have depalmitoylase activity in a reconstitution in-vitro assay. Additionally, CLN5 is known to facilitate trafficking of soluble NCL proteins to the lysosome, suggesting both CLN5 and PPT1 to have similar roles in the regulation of a subset of NCL proteins. Still, more work needs to be done to fully characterize CLN5’s function in the brain and in regulation of other NCL proteins. Previous data show worsened pathology in a PPT1/CLN5 double KO mouse model, implicating synergistic functions between PPT1 and CLN5 with depalmitoylation central to its regulation. Thus, my proposed work will uncover the role of CLN5 in the murine brain and in regulation of lysosomal NCL proteins, and determine whether PPT1/CLN5 cooperatively regulate lysosomal NCL proteins via depalmitoylation. In Aim 1, I will investigate the impact of CLN5 KO on the lysosomal proteome and functional status of lysosomal NCL proteins using organelle immunoprecipitations, mass spectrometry, and Acyl-RAC. I will determine whether NCL protein levels and enzyme activity at the lysosome are affected with CLN5 loss of function, and whether aberrant accumulation of palmitoylated proteins underlies CLN5 KO pathology. In Aim 2, I will test the impact of PPT1/CLN5 deletions on other NCL proteins and lysosomal function and elucidate the function of CLN5 as a trafficking protein or depalmitoylase, and whether PPT1 can ameliorate CLN5 pathology through additional depalmitoylation of NCL proteins. With my current preliminary data pointing towards depalmitoylation impairment in CLN5 KO mice, these experiments will provide crucial information in determining whether NCLs are diseases of aberrant palmitoylation. Overall, we aim to uncover mechanisms underlying lysosomal impairment in NCL, in the hopes of providing therapeutic interventions that would work across the various NCL subtypes.